Literature DB >> 11985489

Mechanisms of fungal resistance: an overview.

Maher M Balkis1, Steven D Leidich, Pranab K Mukherjee, Mahmoud A Ghannoum.   

Abstract

The increased use of antifungal agents in recent years has resulted in the development of resistance to these drugs. The significant clinical implication of resistance has led to heightened interest in the study of antifungal resistance from different angles. In this article we discuss antifungal susceptibility testing, the mode of action of antifungals and mechanisms of resistance. Antifungals are grouped into five groups on the basis of their site of action: azoles, which inhibit the synthesis of ergosterol (the main fungal sterol); polyenes, which bind to fungal membrane sterol, resulting in the formation of aqueous pores through which essential cytoplasmic materials leak out; allylamines, which block ergosterol biosynthesis, leading to accumulation of squalene (which is toxic to the cells); candins (inhibitors of the fungal cell wall), which function by inhibiting the synthesis of beta 1,3-glucan (the major structural polymer of the cell wall); and flucytosine, which inhibits macromolecular synthesis. Different mechanisms contribute to the resistance of antifungal agents. These mechanisms include modification of ERG11 gene at the molecular level (gene mutation, conversion and overexpression), over expression of specific drug efflux pumps, alteration in sterol biosynthesis, and reduction in the intracellular concentration of target enzymes. Approaches to prevent and control the emergence of antifungal resistance include prudent use of antifungals, treatment with the appropriate antifungal and conducting surveillance studies to determine the frequency of resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985489     DOI: 10.2165/00003495-200262070-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  86 in total

1.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

2.  Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models.

Authors:  F C Odds; F Van Gerven; A Espinel-Ingroff; M S Bartlett; M A Ghannoum; M V Lancaster; M A Pfaller; J H Rex; M G Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

Review 3.  Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals.

Authors:  D M Shlaes; D N Gerding; J F John; W A Craig; D L Bornstein; R A Duncan; M R Eckman; W E Farrer; W H Greene; V Lorian; S Levy; J E McGowan; S M Paul; J Ruskin; F C Tenover; C Watanakunakorn
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

4.  Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA.

Authors:  N Osherov; D P Kontoyiannis; A Romans; G S May
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

5.  Mode of action of 5-fluorocytosine.

Authors:  R B Diasio; J E Bennett; C E Myers
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

6.  Cross-resistance to polyene and azole drugs in Cryptococcus neoformans.

Authors:  T Joseph-Horne; D Hollomon; R S Loeffler; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

7.  In-vivo selection of an azole-resistant petite mutant of Candida glabrata.

Authors:  Jean-Philippe Bouchara; Rachid Zouhair; Sandrine LE Boudouil; Gilles Renier; Robert Filmon; Dominique Chabasse; Jean-Noel Hallet; Alain Defontaine
Journal:  J Med Microbiol       Date:  2000-11       Impact factor: 2.472

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; J A Marrinan; W Li; M B Kurtz
Journal:  J Bacteriol       Date:  1994-09       Impact factor: 3.490

View more
  17 in total

1.  The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Nathan P Wiederhold; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 2.  Antifungal effect of plant extract and essential oil.

Authors:  Keyal Uma; Xin Huang; Bhatta Anil Kumar
Journal:  Chin J Integr Med       Date:  2016-09-03       Impact factor: 1.978

3.  Antifungal drug testing by combining minimal inhibitory concentration testing with target identification by gas chromatography-mass spectrometry.

Authors:  Christoph Müller; Ulrike Binder; Franz Bracher; Martin Giera
Journal:  Nat Protoc       Date:  2017-04-06       Impact factor: 13.491

Review 4.  Resistance to antifungals that target CYP51.

Authors:  Josie E Parker; Andrew G S Warrilow; Claire L Price; Jonathan G L Mullins; Diane E Kelly; Steven L Kelly
Journal:  J Chem Biol       Date:  2014-08-27

5.  Antifungal activity screening of fractions from Annona cherimola Mill. leaf extract against Fusarium oxysporum.

Authors:  Manuel Méndez-Chávez; Carlos A Ledesma-Escobar; Madeleine Hidalgo-Morales; Guadalupe Del Carmen Rodríguez-Jimenes; Victor José Robles-Olvera
Journal:  Arch Microbiol       Date:  2022-05-17       Impact factor: 2.552

6.  Chromosome 5 monosomy of Candida albicans controls susceptibility to various toxic agents, including major antifungals.

Authors:  Feng Yang; Anatoliy Kravets; Gabor Bethlendy; Stephen Welle; Elena Rustchenko
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

7.  Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae.

Authors:  Martine Florent; Thierry Noël; Gwenaël Ruprich-Robert; Bruno Da Silva; Valérie Fitton-Ouhabi; Christiane Chastin; Nicolas Papon; Florence Chapeland-Leclerc
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

8.  Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.

Authors:  Florence Chapeland-Leclerc; Christophe Hennequin; Nicolas Papon; Thierry Noël; Aurélie Girard; Gérard Socié; Patricia Ribaud; Claire Lacroix
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

9.  Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans.

Authors:  Li Zhang; Wenqiang Chang; Bin Sun; Matthias Groh; Andreas Speicher; Hongxiang Lou
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

Review 10.  Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides.

Authors:  Letícia S Tavares; Carolina S F Silva; Vinicius C de Souza; Vânia L da Silva; Cláudio G Diniz; Marcelo O Santos
Journal:  Front Microbiol       Date:  2013-12-31       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.